Subjects with Molecularly Defined Familial Hypercholesterolemia or Familial Defective apoB-100 Are Not Being Adequately Treated
2011

Treatment of Familial Hypercholesterolemia and Familial Defective apoB-100

Sample size: 956 publication Evidence: moderate

Author Information

Author(s): Leren Trond P., Berge Knut Erik

Primary Institution: Oslo University Hospital Rikshospitalet, Oslo, Norway

Hypothesis

Are subjects with a molecular genetic diagnosis of familial hypercholesterolemia (FH) or familial defective apoB-100 (FDB) being adequately treated?

Conclusion

The majority of FH/FDB subjects are being diagnosed late in life and are not being adequately treated.

Supporting Evidence

  • Only 47.3% of subjects were considered adequately treated.
  • Among those below 18 years, only 20.4% were on lipid-lowering drugs.
  • 89.1% of those aged 18 and above were on lipid-lowering drugs.
  • 29.0% of those on treatment had LDL cholesterol below 3.0 mmol/l.
  • Mean age for starting lipid-lowering therapy was 33.4 years.

Takeaway

Kids with a genetic condition that makes their cholesterol high aren't getting the medicine they need, which can lead to heart problems when they grow up.

Methodology

A questionnaire was sent to 2611 subjects with a genetic diagnosis of FH or FDB, and blood samples were taken for lipid measurements.

Potential Biases

Self-reported medical history may introduce uncertainties regarding the quality of the information.

Limitations

Only 36.6% of those invited participated, which may lead to selection bias.

Participant Demographics

The mean age of participants was 44.3 years, with 534 females and 422 males.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1371/journal.pone.0016721

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication